In conclusion, the IdyllaTM KRAS Mutation Test on the IdyllaTM platform is to our knowledge the only fully integrated and automated test for detection of 21 clinically relevant mutations included in current guidelines starting from FFPE tissue samples and represents a relevant solution for simple, highly reliable, and rapid routine determination of the KRAS mutational status needed to guide colorectal cancer therapy. This evidence concerns the gene KRAS and colorectal cancer.